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What to do after basal insulin:
3 Tx strategies for type 2 diabetes
These strategies can help you optimize glucose control
in your patient with type 2 diabetes when basal insulin
alone isn’t sufficient.

Practice
recommendations
› Intensify diabetes
treatment for patients who
have a normal fasting
glucose, but an HbA1c >7%
and daytime hyperglycemia,
and for those who are not
at goal despite basal insulin
doses >0.5 units/kg/d. B
› Consider intensifying
diabetes management
beyond basal insulin therapy
by adding a glucagon-like
peptide 1 receptor agonist,
insulin prior to one meal
each day, or insulin
prior to all meals. C

D

iabetes mellitus is a complex, progressive disease that
affects every family physician’s practice. Major diabetes
organizations recommend that treatment be ongoing
and progressive in order to control the disease. The American
Diabetes Association (ADA), the European Association for the
Study of Diabetes (EASD), and the American Association of
Clinical Endocrinologists recommend that patients be assessed
every 2 to 3 months after diagnosis and that treatment should be
intensified if the patient is not meeting treatment goals.1,2 Using
this approach, all people with type 2 diabetes could be on insulin one year after diagnosis.1,2
While many family physicians have become comfortable with using once-daily basal insulin such as glargine or
detemir, what to do after basal insulin is much more complex.
This review builds upon an earlier article in this journal, “Insulin for type 2 diabetes: How and when to get started,”3 by
explaining 3 strategies to consider when basal insulin alone
isn't enough.

Strength of recommendation (SOR)

A Good-quality patient-oriented
evidence

B Inconsistent or limited-quality
patient-oriented evidence

C Consensus, usual practice,
opinion, disease-oriented
evidence, case series
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3 main strategies
for intensifying treatment
Basal insulin is indicated for patients who have glucose
toxicity and persistently elevated hemoglobin A1c (HbA1c)
despite using 2 or more oral agents, or for those who have
not achieved glucose goals one year into treatment.3,4 ADA/
EASD recommends initiating a weight-based approach for
basal insulin therapy based on initial HbA1c levels >7% or
>8%.4 Instructing and encouraging patients to titrate their
own insulin dose based on fasting glucose readings provides
greater and faster glucose control.1,2
Despite these attempts, some patients will not reach their
glucose goals with basal insulin. When intensifying treatment
beyond basal insulin therapy, patient preference, cost-effectiveness, safety, tolerability, glycemic efficacy, risk of hypogly-
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cemia, effects on cardiovascular risk factors,
and other non-glycemic effects should be
considered in the shared decision-making
process. There are 3 main strategies for intensifying treatment:
1. Basal plus incretin therapy. Add
a newer injectable agent such as a
glucagon-like peptide 1 receptor agonist (GLP-1RA).
2. Basal plus one strategy. Add prandial insulin prior to the largest meal of the day.
3. Basal-bolus combination. Add insulin prior to all meals.
provides details of several
studies that have documented the efficacy of
these 3 strategies.
TABLE 1 5-8

Monitoring blood glucose
to guide the way
Blood glucose monitoring using
either a 7-point glucose monitoring technique or staggered glucose checks
should guide insulin
intensification.
A
7-point
glucose
profile includes
pre-meal and
post-meal
readings
for
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3 meals
a day and
an additional
bedtime reading.9 This is typically performed for
3 to 7 days prior to
an appointment and
provides an estimate of
a typical full day’s glucose
pattern.
Staggered monitoring includes a pair of glucose checks taken immediately before and typically
90 minutes after a meal. This is assigned
to a different meal each day in order to ob-
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tain the same information as is achieved with
7-point monitoring, but with fewer checks on
any given day. It may take up to 2 to 3 weeks
to gather the necessary information using the
staggered monitoring technique.
In order to optimize insulin strategies
for tighter glycemic control, it is important to
review blood glucose logs at each office visit
with either of the above techniques.

Basal plus incretin therapy
GLP-1RAs are subcutaneously administered
injectable incretin agents. They mimic the
action of endogenous GLP-1 hormones,
which are normally
secreted in response to meals
by the cells of the
small intestine.10
GLP-1 stimulates glucose-dependent
insulin
secretion, suppresses
postprandial glucagon
release from pancreatic alpha cells, signals satiety, and
slows gastric emptying.10 In
other words, GLP-1 appears to be
a physiologic regulator of appetite
and food intake. GLP-1 is rapidly metabolized and inactivated by dipeptidyl
peptidase-4 (DPP-4) enzymes.10 The amplification of insulin secretion elicited by hormones
secreted from the gastrointestinal (GI) tract is
called the “incretin effect.”10 Obesity, insulin resistance, and type 2 diabetes greatly reduce the
incretin effect.10
GLP-1RAs mimic the incretin effect and
are not degraded by endogenous DPP-4 enzymes.10 They provide a pharmacologic level
of GLP-1 activity, including beneficial glucose effects (via insulin secretion and glucagon suppression), but they also increase GI
adverse effects, such as nausea and vomiting.11-15 Further, they can suppress appetite
and contribute to weight loss.11-15
GLP-1RAs can be considered as an addon therapy for patients whose HbA1c exceeds 7% and whose fasting blood glucose
ranges from 80 to 130 mg/dL, or for patients
with a basal insulin dose >0.5 unit/kg/d. The
5 currently available GLP-1RAs (exenatide,
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Insulin
intensification
should be
guided by
glucose
monitoring
using the 7-point
technique
or staggered
glucose checks.
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TABLE 1

3 ways to intensify type 2 diabetes treatment: A look at the evidence
Study (date)

Patients (N)

Treatment groups

Trial duration

HbA1c

Fasting plasma glucose

1. Albiglutide, 30 mg
weekly titrated to 50 mg
if necessary, plus oncedaily titrated glargine

52 weeks
(26-week
results)

Overall baseline:
8.5%. Decreased
by 0.82% with
albiglutide, 0.66%
with insulin lispro.
Treatment
difference 0.16%
(P<.0001), which
met the non
inferiority endpoint

Similar at baseline (data not
published). Mean was lower in
albiglutide group (P=.236)

6 months
(3-month run-in
period and
3-month
randomized
period)

Overall
baseline: 8.5±0.6%.
Decreased by
0.11±0.08% in
control group,
0.37±0.09% in
glulisine group
(P=.029)

Overall baseline: 143±40 mg/dL.
Decreased to 110±22 mg/dL
(control group) vs 111±22 mg/
dL (glulisine group)

24 weeks

Overall baseline:
7.3±0.7%.
Decreased by 0.5%
in breakfast
glulisine group,
0.6% in main
mealtime glulisine
group (P<.001)

Overall baseline increased
from 6.0±0.8 mmol/L (108±14
mg/dL) to 6.7±1.4 mmol/L
(121±25 mg/dL) in breakfast
group, and from 5.9±0.8
mmol/L (106±14 mg/dL) to
6.3±1.4 mmol/L (113±25 mg/dL)
in main mealtime group

24 weeks

Overall baseline:
7.8%. Decreased by
0.44% in 1X group,
0.36% in 2X group,
0.43% in 3X group
(NS)

Overall baseline:
131 mg/dL. Data (not
published) was reported
as comparable in all groups
at the end of study

Basal plus GLP-1RA
Rosenstock J,
et al5 (2014)

586; average
DM duration
11 years

2. T
 itrated preprandial
insulin lispro 3 times/d
plus once-daily titrated
glargine

Basal plus one
Owens DR,
et al6 (2011)

Lankisch MR,
et al7 (2008)

106; average
DM duration
11.5±7 years

1. G
 largine daily with OHA
(control group)

393; average
DM duration
10 years

1. Addition of glulisine at
breakfast to existing
glargine regimen

2. Addition of glulisine
to the main meal with
glargine and OHA
(glulisine group)

2. Addition of glulisine
at main mealtime
to existing glargine
regimen
Basal-bolus combination
Davidson MB,
et al8 (2011)

341; average
DM duration
10 years

1. One insulin glulisine
injection with the
largest meal of the day
(1X group)
2. One glulisine injection
prior to 2 meals/d
(2X group)
3. One glulisine injection
prior to 3 meals/d
(3X group)

BG, blood glucose; DM, diabetes mellitus; HbA1c, hemoglobin A1c; NS, not significant; OHA, oral hypoglycemic agent.

exenatide extended-release, liraglutide, albiglutide, and dulaglutide) are compared in
TABLE 2.11-15
Dosing varies with each agent and includes twice daily before meals for exenatide, once daily (independent of meals) for
liraglutide, and once weekly for exenatide extended-release, albiglutide, and dulaglutide.
These agents should not be used for patients
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with a history of pancreatitis or a personal or
family history of medullary thyroid cancer or
multiple endocrine neoplasia type 2. Because
exenatide is cleared through the kidneys, its
use is contraindicated in patients with a creatinine clearance <30 mL/min or end-stage
renal disease. Caution is advised for its use in
patients with a creatinine clearance of 30 to
50 mL/min.11
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Conclusions

After 26 weeks, HbA1c reduction, goal HbA1c
<7%, and goal HbA1c <6.5% was comparable and
noninferior in both treatment groups. Weight was
significantly lower in the albiglutide group. Adverse
reactions were comparable. Findings supports
noninferiority between albiglutide and insulin lispro
and a weight-loss benefit with albiglutide

HbA1c <7% at 6 months was reached more
frequently by participants in the glulisine group
than those in the control group. Findings support
the rationale, safety, and efficacy of adding a single
dose of glulisine to ongoing glargine plus OHAs to
improve HbA1c and mean daily plasma BG when
HbA1c targets have not been met
Glulisine given at breakfast was equally effective
in controlling HbA1c as glulisine given at the main
mealtime. Significantly more patients achieved
target HbA1c ≤7% in the main mealtime group.
Changes in weight (NS) and rates of hypoglycemia
(NS) were comparable in both groups

At 24 weeks, HbA1c reductions was noninferior
among 1X or 2X groups compared to 3X group.
However, a greater number of patients achieved
HbA1c <7% in the 3X group (46%) vs the
1X (34%) and 2X (30%) groups (P=.17 and P=.045,
respectively). Findings confirm that a regimen with
multiple daily injections is more likely to reach
target HbA1c levels without a significant impact
on weight or hypoglycemia

Basal plus one strategy
To best utilize prandial insulin, it is important
to know what the patient’s glucose readings
are before and after meals as assessed by the
7-point or staggered blood glucose monitoring techniques described earlier. Once you
have clarified which meal(s) are raising the
patient’s glucose levels, selecting appropriate treatment becomes easier. To reduce the

glucose-monitoring burden for the patient, it
may be acceptable to allow the patient to omit
the fasting glucose measurement (if stable).
The first major decision is whether to
treat one meal per day (basal plus one) or all
meals (basal-bolus). Adding a rapid-acting
insulin prior to one meal a day (usually the
largest meal) is a reasonable starting point.16
The meal that produces the highest postprandial glucose readings can be considered
the meal of greatest glycemic impact. The
“delta” value—the difference between premeal glucose and 2-hour postprandial glucose readings—also helps to determine the
largest meal of the day.17 The average physiologic delta is ≤50 mg/dL.17 If the delta for a
meal is >75 mg/dL, consider initiating prandial insulin prior to that meal and titrating
the dose to achieve a target glucose level of
<130 mg/dL before the next meal.
Using 4 to 6 units of a rapid-acting insulin per meal is a good initial regimen for a
basal plus one (as well as for a basal-bolus)
approach.16 If the patient experiences significantly increased insulin demands as indicated by glucose patterns where the post-meal
glucose is still consistently above 180 mg/dL,
the initial regimen may be modified to
0.1 unit per kg per meal,17-19 and then titrated up
to a maximum of 50% of the total daily insulin
dose (TDD) for basal plus one16 (or 10%-20% of
TDD per meal for basal-bolus).

A GLP-1RA can
be considered
for patients with
an HbA1c >7%
and a fasting
glucose ranging
from 80 to
130 mg/dL.

z Consider the timing of administration. Rapid-acting insulin analogs exhibit

peak pharmacodynamic activity 60 minutes
after injection (TABLE 3 ).20
Peak carbohydrate absorption following
a meal occurs approximately 75 to 90 minutes
after eating begins.17,21 Thus, to synchronize
the action of insulin with carbohydrate digestion, the analog should be injected 15 minutes before meals. This can be increased by
titrating prandial insulin by 1 unit/d to a goal
of either a 90-minute to 2-hour postprandial
glucose of <140 to 180 mg/dL or the next preprandial glucose of <130 mg/dL.16 The goal
is to obtain a near-normal physiologic delta
of <50 mg/dL. The drop in delta noted with
every unit of insulin added to the current
dose can provide a rough approximation of
how many additional insulin titrations will be
needed to achieve a delta of <50 mg/dL.
c o nti n u ed
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TABLE 2

GLP-1 receptor agonists used to treat type 2 diabetes*
Medication

Dosing frequency

Renal dosing

Relation to meals

Warnings/precautions*

Exenatide

Twice daily
(5 mcg, 10 mcg)

Caution for Cr Clr
of 30-50 mL/min

30-60 minutes before
am and pm meals

Pancreatitis; thyroid C-cell
cancer; avoid use with Cr Clr
<30 mL/min

Exenatide
extended-release12

Once weekly
(2 mg)

Caution for Cr Clr
of 30-50 mL/min

Not related to meals

Pancreatitis; thyroid
C-cell cancer; avoid use with
Cr Clr <30 mL/min or ESRD

Liraglutide13

Once daily
(0.6 mg, 1.2 mg, 1.8 mg)

Caution for Cr Clr
of 30-50 mL/min

Not related to meals

Pancreatitis; thyroid
C-cell cancer; MEN type 2

Albiglutide14

Once weekly
(30 mg, 50 mg)

No dosage adjustment

Not related to meals

Medullary thyroid
cancer

Dulaglutide15

Once weekly
(0.75 mg, 1.5 mg)

No dosage adjustment

Not related to meals

Thyroid C-cell tumors. Not
studied with pancreatitis

11

Cr Clr, creatinine clearance; ESRD, end-stage renal disease; GLP-1, glucagon-like peptide 1; MEN, multiple endocrine neoplasia.
* Nausea is a common adverse effect of all GLP-1 receptor agonists; for some of these agents, weight loss and vomiting also are common. All GLP-1 receptor
agonists are pregnancy category C.

Basal-bolus combination
A gradual increase from one injection before
a single meal each day to as-needed multiple
daily injections (MDIs) is the next step in hyperglycemia management. Starting slow and
building up to insulin therapy prior to each
meal offers structure, simplicity, and physician-patient confidence in diabetes management. The slow progression from basal plus
one to basal-bolus combination allows the
patient ease into a complex, labor-intensive
regimen of MDIs. Additionally, the stepwise
reduction of postprandial hyperglycemia with
this slow approach often reduces the incidence
of hypoglycemia (more on this in a moment).8
Advanced insulin users can calculate an
“insulin-to-carbohydrate ratio” (ICR) to estimate the amount of insulin they need to accommodate the amount of carbohydrates they
ingest per meal. An ICR of 1:10 implies that the
patient administers 1 unit of insulin for every
10 grams of carbohydrates ingested. For example, if a patient with an ICR of 1:10 concludes
that his meal contains a total of 60 grams of carbohydrates, then he would administer 6 units
of insulin prior to this meal to address the anticipated post-meal hyperglycemia.
In order to use the ICR regimen, a patient would need to be able to accurately determine the nutritional content of his meals
(starch, protein, carbohydrates, and fat) and
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calculate the appropriate insulin dosage. For
successful diabetes management, it is essential to evaluate the patient’s skills in these
areas before starting an ICR regimen, and to
routinely assess hypoglycemic episodes at
follow-up visits.
An ICR approach is usually reserved for
patients who require tighter glucose control
than that obtained from fixed prandial insulin doses, such as patients with type 1 diabetes, those with variable meal schedules and
content, those with a malabsorption syndrome that requires consuming meals with a
specific amount of carbohydrates, athletes on
a structured diet with specific carbohydrate
content, and patients who want flexibility
with carbohydrate intake with meals.
z The risk of hypoglycemia is a major
barrier to initiating basal-bolus insulin therapy. Hypoglycemia is classified as a blood
glucose level of <70 mg/dL, and severe hypoglycemia as <50 mg/dL, regardless of whether
the patient develops symptoms.22 Symptoms
of hypoglycemia include dizziness, difficulty
speaking, anxiety, confusion, and lethargy.
Hypoglycemia can result in loss of consciousness or even death.22
A patient who has frequent hypoglycemic
episodes may lose the protective physiologic
response and may not recognize that he is
experiencing a hypoglycemic episode (“hypo-
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TABLE 3

Time-action profiles for short-acting
and rapid-acting insulin analogues20
Insulin type

Onset (h)

Peak (h)

Duration (h)

Regular (short-acting)

0.5

2-4

6-8

Aspart (rapid-acting)

≤0.25

1-3

3-5

Lispro (rapid-acting)

≤0.25

1

2-4

Glulisine (rapid-acting)

≤0.25

1

3.5-4.5

glycemia unawareness”). This is why it is crucial to ask patients if they have had symptoms
of hypoglycemia, and to correlate the timing of
these symptoms with blood glucose logs. For
example, it is possible for a patient to experience hypoglycemic symptoms for blood glucose readings in the 100 to 200 mg/dL range
if his or her average blood glucose has been in
the 250 to 300 mg/dL range. Such patient may
not realize he is experiencing hypoglycemia
until he develops severe symptoms, such as
loss of consciousness.
Hypoglycemia unawareness must be addressed immediately by reducing insulin dosing to prevent all hypoglycemic episodes for
2 to 3 weeks. This has been shown to “reset”
the normal physiologic response to hypo-

glycemia, regardless of how long the patient
has had diabetes.23,24 Even if your patient is
aware of the warning signs of a hypoglycemic
episode, it is important to routinely ask about
hypoglycemia at all diabetes visits because patients may reduce insulin doses, skip doses, or
eat defensively to prevent hypoglycemia.
Other than the risk of hypoglycemia, insulin typically has fewer adverse effects than
oral medications used to treat diabetes. Most
common concerns include weight gain, hypoglycemia, injection site reactions and,
rarely, allergy to insulin or its vehicle.16
JFP

Adding a rapidacting insulin
prior to one
meal a day is
a reasonable
starting point
for intensifying
insulin therapy.

CORRESPONDENCE

Jay Shubrook, DO, FAAFP, FACOFP, BC-ADM, Touro
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Drive, Vallejo, CA 94592; jay.shubrook@tu.edu
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